Ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors have been reported in a Simcere Zaiming Pharmaceutical Co. Ltd. patent as potentially useful for the treatment of cancer.
Research at Japan Tobacco Inc. has led to the development of 6-aminopyrazolopyrimidine compounds acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of arteriosclerosis, gout, inflammatory bowel disease, amyotrophic lateral sclerosis, multiple sclerosis, nonalcoholic steatohepatitis (NASH), Alzheimer’s and Parkinson’s diseases.
One of the well-established mechanisms of multidrug resistance (MDR) to chemotherapy in cancer patients is ATP binding cassette (ABC) transporter overexpression in cancer cell membrane, and as the most extensively characterized ABC transporter, P-glycoprotein (P-gp) is considered a potential target to overcome MDR. In a recent publication, researchers from Xuzhou Medical University detailed the discovery of novel P-gp inhibitors as candidates to overcome MDR to chemotherapy.
Recent studies indicate that the hyperactivation of the PD-1/PD-L1 axis in Alzheimer’s disease (AD) brain has an influence on disease pathophysiology. With this in mind, researchers from Sungkyunkwan University evaluated INR-301, a novel superior blood-brain barrier (BBB)-penetrating anti-PD-L1 antibody, in an AD model.
Arcus Biosciences Inc. has reported the discovery and SAR-driven optimization and characterization of potent novel tyrosine-protein kinase receptor UFO (AXL) inhibitors for the potential treatment of cancer.
RSS
